371 KB29 KB200520252019Zidar, Naceštevilka:1letnik:70str. 19-26ISSN:0014-8229COBISSID_HOST:4721521URN:URN:NBN:SI:doc-2PMCBO9WslSlovensko farmacevtsko društvoFarmacevtski vestnikmetforminperoralni antidiabetikSladkorna bolezen tip 2sulfonilsečninazaviralecPeroralni antidiabetiki - pregled stanja in pogled v prihodnost| Oral antidiabetic drugs - current overview and future perspectives|Type 2 diabetes mellitus is a chronic progressive metabolic disorder that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Because of their effectiveness and convenience of administration, oral antidiabetic drugs are frequently prescribed for the treatment of type 2 diabetes mellitus. Metformin and sulfonylureas are among the most known oral antidiabetic drugs and have been used in the clinic for more than 50 years. In addition, several other classes of drugs are known, such as meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium/glucose cotransporter 2 (SGLT-2) inhibitors. The number of available therapies for the treatment of type 2 diabetes has grown considerably in recent years. In this paper, we present an overview of clinically approved oral antidiabetic agents and some new classes of drugs that are currently in different stages of developmentSladkorna bolezen tipa 2 je kronična progresivna metabolna bolezen, ki nastane, ko trebušna slinavka ne proizvede dovolj inzulina ali kadar človeško telo proizvedenega inzulina ne uspe učinkovito izrabiti. Zaradi njihove učinkovitosti in enostavnosti jemanja za preprečevanje hiperglikemije pri pacientih s sladkorno boleznijo tipa 2 pogosto uporabljamo peroralne antidiabetike. Med najbolj uveljavljene uvrščamo metformin in sulfonilsečnine, ki so v uporabi že več kot 50 let. Poleg teh pa v terapiji uporabljamo še številne druge skupine učinkovin, kot so meglitinidi, tiazolidindioni, zaviralci alfa-glukozidaze, zaviralci dipeptidil-peptidaze 4 (DPP-4) in zaviralci kotransporterja natrijevih ionov in glukoze 2 (SGLT-2). Število učinkovin za zdravljenje sladkorne bolezni tipa 2 se je v zadnjih letih močno povečalo. V članku predstavljamo pregled obstoječih skupin peroralnih antidiabetikov in nekatere novejše skupine učinkovin, ki so v različnih fazah razvojaTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo